W. Wuyts (Leuven, Belgium), F. Hernandez Gonzalez (Barcelona, Spain)
Introduction
W. Wuyts (Leuven, Belgium), F. Hernandez Gonzalez (Barcelona, Spain)
|  |
Assessment of a relationship between prognostic biomarkers and treatment response in ISABELA1 &2 IPF cohorts
M. Randall (Basel, Switzerland), S. De Bernard (Lyon, France), I. Seghers (Mechelen, Belgium), N. Verbruggen (Mechelen, Belgium), S. Lim (Foster City, United States), B. Van Den Blink (Mechelen, Belgium), C. Andersen (Mechelen, Belgium), P. Pujuguet (Romainville, France), N. Prasad (Mechelen, Belgium), P. Ford (Mechelen, Belgium), Y. Bauer (Basel, Switzerland)
|    |
Nocturnal hypoxaemia is associated with mortality in patients with fibrotic interstitial lung disease
K. Myall (London, United Kingdom), J. Martinovic (London, United Kingdom), Z. Wu (London, United Kingdom), J. Lam (London, United Kingdom), D. Roque (London, United Kingdom), V. Jardim (London, United Kingdom), D. Jackson (London, United Kingdom), E. Suh (London, United Kingdom), T. Maher (London, United Kingdom), P. Molyneaux (London, United Kingdom), B. Kent (Dublin, Ireland), A. West (London, United Kingdom)
| |
Outcomes of patients managed in specialised compared to non-specialised ILD centres
P. Marijic (Neuherberg, Germany), L. Schwarzkopf (Neuherberg, Germany), W. Maier (Neuherberg, Germany), F. Trudzinski (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), L. Schwettmann (Neuherberg, Germany)
| |
Predicting treatment response in patients with interstitial lung disease using electronic nose technology
I. van der Sar (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), B. Vellekoop (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
| |
Family history of ILD predicts pulmonary function decline in IPF patients
T. Goos (Leuven, Belgium), M. Vermant (Leuven, Belgium), L. De Sadeleer (Leuven, Belgium), K. Verstraete (Leuven, Belgium), N. De Crem (Leuven, Belgium), E. De Langhe (Leuven, Belgium), A. Dubbeldam (Leuven, Belgium), E. Verbeken (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), B. Weynand (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), S. Vermeer (Leuven, Belgium), S. Verleden (Antwerp, Belgium), W. Wuyts (Leuven, Belgium)
| |
Association of mUC5B rs35705950 minor allele with age and survival in European patients with Idiopathic Pulmonary Fibrosis
J. van der Vis (Nieuwegein, Netherlands), A. Prasse (Hannover, Germany), E. Renzoni (London, United Kingdom), C. Stock (London, United Kingdom), C. Caliskan (Hannover, Germany), T. Maher (London, United Kingdom), F. Bonella (Essen, Germany), R. Borie (Paris, France), B. Crestani (Paris, France), M. Petrek (Olomouc, Czech Republic), W. Wuyts (Leuven, Belgium), A. Wind (Nieuwegein, Netherlands), P. Molyneaux (London, United Kingdom), J. Grutters (Nieuwegein, Netherlands), C. Van Moorsel (Nieuwegein, Netherlands)
| |
Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression
T. Ogura (Yokohama, Japan), R. Okuda (Yokohama, Japan), N. Ishikawa (Hiroshima, Japan), T. Suda (Hamamatsu, Japan), N. Arai (Ibaraki, Japan), T. Takihara (Isehara, Japan), M. Hamaguchi (Izumo, Japan), Y. Kondoh (Seto, Japan), M. Toyoshima (Hamamatsu, Japan), K. Tomii (Kobe, Japan), M. Abe (Chiba, Japan), M. Kato (Tokyo, Japan), M. Kagajo (Ogaki, Japan), Y. Shimizu (Souka, Japan), H. Tomioka (Kobe, Japan), K. Kawamura (Kumamoto, Japan), K. Honda (Tokyo, Japan), Y. Nishioka (Tokushima, Japan), M. Tanigawa (Ise, Japan), H. Chiba (Sapporo, Japan), S. Izumi (Tokyo, Japan), K. Tobino (Iizuka, Japan), H. Yamauchi (Shimotsuke, Japan), T. Kawamura (Himeji, Japan), M. Inomata (Tokyo, Japan), K. Usui (Tokyo, Japan), H. Ohkubo (Nagoya, Japan), H. Matsushima (Saitama, Japan), Y. Oyamada (Tokyo, Japan), T. Jokoh (Amagasaki, Japan), T. Arai (Osaka, Japan), T. Iwasawa (Yokohama, Japan), F. Sakai (Yokohama, Japan), S. Morita (Kyoto, Japan), N. Ichihara (Tokyo, Japan), T. Nukiwa (Sendai, Japan), K. Kobayashi (Hidaka, Japan), J. Registry Members (Yokohama, Japan)
| |
Late Breaking Abstract - An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis
T. Maher (Los Angeles, United States), W. Forbes (New Haven, United States), E. Bortey (New Haven, United States), T. Sciascia (New Haven, United States)
| |
Late Breaking Abstract - Additive effect of BI 1015550 and nintedanib in patients with IPF
L. Richeldi (Roma, Italy), A. Azuma (Tokyo, Japan), V. Cottin (Lyon, France), C. Hesslinger (Biberach, Germany), S. Stowasser (Ingelheim, Germany), C. Valenzuela (Madrid, Spain), M. Wijsenbeek (Rotterdam, Netherlands), D. Wachtlin (Ingelheim, Germany), D. Zoz (Ridgefield, United States), T. Maher (Los Angeles, United States)
| |
Late Breaking Abstract - Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis
T. Maher (Los angeles, United States), C. Ganslandt (Stockholm, Sweden), R. Batta (Stockholm, Sweden), G. Tornling (Stockholm, Sweden), T. Bengtsson (Stockholm, Sweden), H. Pophale (Mumbai, India), E. Rosendahl (Stockholm, Sweden), T. Maher (Los Angeles, United States)
| |
Discussion
| |